产品说明书

Moexipril HCl

Print
Chemical Structure| 82586-52-5 同义名 : 莫昔普利盐酸盐 ;RS-10085;Moexipril (hydrochloride);SPM 925;RS 10085-197;CI-925;Moexipril hydrochloride
CAS号 : 82586-52-5
货号 : A232444
分子式 : C27H35ClN2O7
纯度 : 98%
分子量 : 535.029
MDL号 : MFCD00940481
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 250 mg/mL(467.26 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(186.91 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • ACE
描述 Moexipril HCl is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure[3]. Moexipril alone and in combination with low-dose hydrochlorothiazide has been shown in clinical trials to be effective in lowering blood pressure and be well tolerated and safe given in single daily doses[4]. Equidose treatment (10 mg/kg/day) with moexipril and enalapril over 4 weeks led to comparable decreases in blood pressure, inhibition of plasma ACE and reduction of plasma angiotensinogen and to a similar attenuation of the pressor responses to angiotensin I and potentiation of the depressor responses to bradykinin[5]. Moexipril is effective and well tolerated in the treatment of hypertensive, postmenopausal women and can safely be co-administered to HRT (hormonal replacement therapy) [6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01867047 Adverse Effects of Angiotensin... 展开 >>-converting-enzyme Inhibitors Hypotension 收起 << Not Applicable Terminated(Following an interi... 展开 >>m analysis the study team felt that there was enough data that showed no significant difference.) 收起 << - United States, North Carolina ... 展开 >> Duke University Durham, North Carolina, United States, 27710 收起 <<
NCT01669434 - Completed - -
NCT01669434 Hypotension on Induction Phase 4 Completed - United States, Nebraska ... 展开 >> University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.35mL

1.87mL

0.93mL

18.69mL

3.74mL

1.87mL
参考文献

[1]Ravati A, Junker V, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373(1):21-33.

[2]Ma YF, Stimpel M, et al. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol. 1997 Sep;154(3):467-74.

[3]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Moexipril. 2018 Feb 11

[4]Chrysant SG, Chrysant GS. Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36

[5]Edling O, Bao G, Feelisch M, Unger T, Gohlke P. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63

[6]Koch B, Oparil S, Stimpel M. Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. J Hum Hypertens. 1999 May;13(5):337-42